Obefazimod combo partner unveiled, and monotherapy data at UEG
Abivax unveiled the identity of the first moelcule selected for development in a fixed-dose combination with obefazimod, namely Pfizer's Etrasimod (Velsipity), Pfizer launched this S1P inhibitor in Oct. 2023 in moderate to severe ulcerative colitis. Abivax pointed at intriguing synergetic effects i
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.